InnoModels Biotechnology has long been committed to advancing research and development in the field of antibody-dependent cytotoxicity (ADCC) in order to improve the efficacy of cancer therapies. In this journey of discovery, we are proud to introduce the innovative CDC In Vitro Immuno-Tumour Cell Co-Culture Killing Experiment Platform, which provides researchers with a powerful and precise tool that promises to drive innovation in cancer treatment.
Experimental platform features
1. Simulates in vivo environment:
The CDC in vitro immune-tumour cell co-culture and killing experimental platform can simulate the complex immune microenvironment in vivo, providing an experimental system that is closer to real physiological conditions. This helps to more accurately assess the effects of potential therapeutic drugs in the immune system.
2. Accurate simulation of immune cell interactions:
The experimental platform enables complex interactions between antibodies, immune cells and tumour cells through carefully designed in vitro conditions. This includes clever simulations of antibody binding to tumour cells, immune cell activation and killing processes, enabling researchers to gain a more comprehensive understanding of the mechanisms of ADCC.
3. High-throughput automation:
To improve experimental efficiency, our platform employs high-throughput automation technology, which is capable of processing multiple samples simultaneously for large-scale data collection and analysis. This enables researchers to assess the effects of different treatment regimens more quickly and comprehensively.
4. Flexibility and customisation:
Our platform is designed to be flexible and can be customised according to the needs of researchers. This allows experiments to be better adapted to different cancer types and individual patient differences, supporting the development of personalised treatment plans.

Application Areas
The CDC in vitro immune-tumour cell co-culture killing experimental platform has a wide range of applications in cancer therapy research, including but not limited to:
Drug screening and evaluation:
Rapidly and accurately assess the ADCC effects of potential therapeutic agents, providing important information for drug development.
Mechanistic studies:
In-depth exploration of the molecular mechanisms of ADCC, revealing the interaction between therapeutic agents and the immune system.
Personalised therapy:
Tailor the treatment plan based on patients' immune characteristics to improve the relevance and efficacy of treatment.
Biomarker Identification:
Discover and validate biomarkers associated with the effects of ADCC, providing a basis for clinical translation.
Conclusion.
The launch of the CDC in vitro immune-tumour cell co-culture killing experimental platform marks the unremitting efforts of InnoModels Biotechnology in the field of ADCC research. We believe that the wide application of this platform will open a brand new chapter for the future of cancer treatment, provide patients with more personalised and precise treatment plans, and help medical science and technology to move forward.